Antitrust Investigation Targets Novo Nordisk and Sanofi Over Insulin Pricing in South Africa

In a significant development in the pharmaceutical sector, Danish pharmaceutical giant Novo Nordisk along with French company Sanofi is facing scrutiny from South African authorities concerning possible antitrust violations related to insulin pricing. The investigation aims to explore whether these companies engaged in unfair practices that may have contributed to the increased costs of insulin, a critical medication for diabetics, thus affecting public health.

Continue reading